-
-
-
-
-
-
-
Adicet Bio Announces Reverse Stock Split
-
-
-
-
-
-
-
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
-
-
-
-
-
-
-
Adicet Bio (ACET) Appoints Michael Grissinger to the Board of Directors
-
-
-
-
-
-
-
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
-
-
-
-
-
-
-
Adicet Bio (ACET) Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
-
-
-
-
-
-
-
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
-
1,197,253 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

